Clinical trials: MSS
Colorectal Cancer
A Trial of SHR-1210 in Combination With AIN457 in Patients With MSS CRC（SHR-1210-AIN457）
This is a Phase Ib/IIa, Open-label, Investigator-initiated Trail of SHR-1210 (an Anti-PD-1 Inhibitor) in combination with AIN457 for patients with late stage MSS CRC who failed second-line and above treatment.
- Trial name
- NCT04298320
- Testing
- SHR-1210, AIN 457
- Volunteers
- 40 people
- Sponsor
- Yanqiao Zhang
Colorectal Cancer
A Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatment for MSS/pMMR Metastatic Colorectal Cancer With BRAF V600E Mutation
This is an open-label, single-arm, single-center phase II clinical study, aiming to investigate the safety and efficacy of Aipalolitovorelizumab (QL1706) combined with bevacizumab plus standard chemotherapy regimen as first-line…
- Trial name
- NCT07229846
- Testing
- Aipalolitovorelizumab, XELOX + Bevacizumab, mFOLFOX + Bevacizumab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Yanqiao Zhang
Colorectal Cancer Metastatic
BAL/BOT/agenT-797 in pMMR CRC With Liver Metastases
The goal of this clinical trial is to learn whether the combination of balstilimab, botensilimab, and agenT-797 is safe and effective in treating adults with previously treated metastatic colorectal cancer that is microsatellite…
- Trial name
- NCT07550088
- Testing
- Balstilimab (BAL), Botensilimab (BOT), agenT-797
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Darren Sigal, MD
Locally Advanced, High-Risk
Toripalimab Combined With Neoadjuvant Chemoradiotherapy as First-line Treatment for Locally Advanced，High-Risk，MSS Rectal Cancer
This is a single arm, open-label, prospective clinical trial to evaluate the combination of neoadjuvant short-course radiotherapy and toripalimab (PD-1 antibody) for locally advanced rectal cancer (LARC) patients with high risk…
- Conditions
- Locally Advanced, High-Risk, Rectal Cancer, MSS
- Trial name
- NCT05877573
- Testing
- Toripalimab, short-term radiotherapy, Oxaliplatin
- Where
- China
- Volunteers
- 53 people
- Sponsor
- Nanfang Hospital, Southern Medical University